Mental Depression

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Mental Depression

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 12 29 15 71
Depressive Disorder 71
Depression 44


External Ids:

Disease Ontology 12 DOID:1596
MeSH 44 D003863
NCIt 50 C2982
SNOMED-CT 67 41006004
ICD10 32 F32.9
UMLS 71 C0011570 C0011581

Summaries for Mental Depression

MalaCards based summary : Mental Depression, also known as depressive disorder, is related to postpartum depression and major depressive disorder, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is DCTN1 (Dynactin Subunit 1), and among its related pathways/superpathways are cAMP signaling pathway and Serotonergic synapse. The drugs Reboxetine and Parathyroid hormone have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Mental Depression

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1982)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 33.1 SLC6A4 OXT NR3C1 MAOA HTR1A CRH
2 major depressive disorder 32.9 SLC6A4 POMC OXT NR3C1 MAOA IL6
3 bipolar disorder 32.8 SLC6A4 PRODH NR3C1 MAOA IL6 HTR2A
4 atypical depressive disorder 32.5 SLC6A4 SERPINA3 POMC NR3C1 MAOA IL6
5 traumatic brain injury 32.4 IL6 COMT BDNF
6 eating disorder 32.4 SLC6A4 POMC CRH COMT BDNF
7 neurotic disorder 32.4 SLC6A4 POMC OXT MAOA IL6 HTR2A
8 anxiety 32.3 SLC6A4 PRODH POMC OXT NR3C1 MAOA
9 headache 32.3 SLC6A4 HTR2A COMT
10 fibromyalgia 32.3 SLC6A4 POMC IL6 HTR2A CRH COMT
11 alcohol use disorder 32.3 SLC6A4 HTR2A HTR1A H2AC18 CRH COMT
12 depression 32.2 SLC6A4 NR3C1 MAOA HTR2A HTR1A CRH
13 schizoaffective disorder 32.2 SLC6A4 PRODH HTR2A HTR1A COMT BDNF
14 mood disorder 32.2 SLC6A4 PRODH POMC NR3C1 MAOA IL6
15 sleep apnea 32.2 SLC6A4 IL6 HTR2A BDNF
16 melancholia 32.1 SLC6A4 POMC MAOA IL6 HTR2A HTR1A
17 dysthymic disorder 32.1 SLC6A4 PRODH POMC MAOA IL6 HTR2A
18 dementia, lewy body 32.1 SERPINA3 H2AC18 COMT BDNF
19 asperger syndrome 32.0 SLC6A4 OXT COMT BDNF
20 cyclothymic disorder 32.0 SLC6A4 HTR2A COMT
21 gilles de la tourette syndrome 32.0 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
22 migraine with or without aura 1 32.0 SLC6A4 POMC OXT MAOA IL6 HTR2A
23 parkinson disease, late-onset 32.0 SLC6A4 SERPINA3 PRODH MIRLET7D MAOA HTR2A
24 body dysmorphic disorder 32.0 SLC6A4 OXT MAOA HTR2A
25 generalized anxiety disorder 32.0 SLC6A4 NR3C1 MAOA HTR2A HTR1A COMT
26 bulimia nervosa 32.0 SLC6A4 OXT MAOA HTR2A COMT BDNF
27 schizotypal personality disorder 31.9 PRODH HTR2A COMT
28 restless legs syndrome 31.9 SLC6A4 POMC MAOA COMT
29 post-traumatic stress disorder 31.9 SLC6A4 POMC NR3C1 MAOA HTR2A FKBP5
30 conversion disorder 31.9 HTR2A CRH COMT BDNF
31 brain injury 31.9 IL6 COMT BDNF
32 borderline personality disorder 31.8 SLC6A4 NR3C1 MAOA HTR2A HTR1A FKBP5
33 tardive dyskinesia 31.8 HTR2A COMT
34 panic disorder 31.8 SLC6A4 POMC MAOA HTR2A HTR1A CRH
35 acth-secreting pituitary adenoma 31.8 POMC NR3C1 CRH
36 personality disorder 31.8 SLC6A4 NR3C1 MAOA HTR2A HTR1A FKBP5
37 obsessive-compulsive disorder 31.8 SLC6A4 POMC OXT MAOA IL6 HTR2A
38 alcohol dependence 31.7 SLC6A4 POMC MAOA HTR2A HTR1A CRH
39 back pain 31.7 IL6 COMT
40 schizophrenia 31.7 SLC6A4 SERPINA3 PRODH POMC OXT NR3C1
41 arteries, anomalies of 31.7 SERPINA3 MIRLET7D MIR144 IL6 H2AC18
42 alexithymia 31.6 SLC6A4 OXT IL6 HTR1A COMT
43 autism spectrum disorder 31.6 SLC6A4 PRODH POMC OXT NR3C1 MAOA
44 respiratory failure 31.6 SERPINA3 IL6 H2AC18 DCTN1
45 bipolar i disorder 31.5 SLC6A4 HTR2A HTR1A COMT BDNF
46 conduct disorder 31.5 SLC6A4 POMC MAOA COMT
47 pulmonary disease, chronic obstructive 31.5 SLC6A4 SERPINA3 NR3C1 MIR144 IL6 H2AC18
48 endogenous depression 31.5 SLC6A4 POMC OXT NR3C1 MAOA IL6
49 acute stress disorder 31.5 SLC6A4 SERPINA3 POMC OXT NR3C1 IL6
50 substance abuse 31.5 SLC6A4 SERPINA3 PRODH POMC MAOA IL6

Graphical network of the top 20 diseases related to Mental Depression:

Diseases related to Mental Depression

Symptoms & Phenotypes for Mental Depression

UMLS symptoms related to Mental Depression:

dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

MGI Mouse Phenotypes related to Mental Depression:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 BDNF COMT CRH DCTN1 FKBP5 HTR1A
2 homeostasis/metabolism MP:0005376 10.03 BDNF COMT CRH DCTN1 DPP4 FKBP5
3 endocrine/exocrine gland MP:0005379 9.96 BDNF COMT CRH DPP4 HTR2A IL6
4 integument MP:0010771 9.61 BDNF CRH IL6 NR3C1 OXT POMC
5 nervous system MP:0003631 9.44 BDNF COMT CRH DCTN1 FKBP5 HTR1A

Drugs & Therapeutics for Mental Depression

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 751)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Reboxetine Approved, Experimental Phase 4 71620-89-8, 98769-81-4 123628 65856
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
Oxcarbazepine Approved Phase 4 28721-07-5 34312
Methimazole Approved Phase 4 60-56-0 1349907
Eleuthero Approved, Experimental Phase 4
Lactulose Approved Phase 4 4618-18-2 11333
Copper Approved, Investigational Phase 4 7440-50-8 27099
Norethindrone Approved Phase 4 68-22-4 6230
Lithium carbonate Approved Phase 4 554-13-2
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Ziprasidone Approved Phase 4 146939-27-7 60854
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
Haloperidol Approved Phase 4 52-86-8 3559
Desipramine Approved, Investigational Phase 4 50-47-5 2995
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
Testosterone enanthate Approved Phase 4 315-37-7 9416
Methyltestosterone Approved Phase 4 58-18-4 6010
Topiramate Approved Phase 4 97240-79-4 5284627
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
Donepezil Approved Phase 4 120014-06-4 3152
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Sodium citrate Approved, Investigational Phase 4 68-04-2
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
Trimipramine Approved Phase 4 739-71-9 5584 4055
Clozapine Approved Phase 4 5786-21-0 2818
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
Maprotiline Approved, Investigational Phase 4 10262-69-8 4011
Protriptyline Approved Phase 4 438-60-8 4976
Isocarboxazid Approved Phase 4 59-63-2 3759
Moclobemide Approved, Investigational Phase 4 71320-77-9 4235
Methadone Approved Phase 4 76-99-3 4095
Calcium carbonate Approved, Investigational Phase 4 471-34-1
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
Ribavirin Approved Phase 4 36791-04-5 37542
Iloperidone Approved Phase 4 133454-47-4 71360
Ondansetron Approved Phase 4 99614-02-5 4595
Zolpidem Approved Phase 4 82626-48-0 5732
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554

Interventional clinical trials:

(show top 50) (show all 7191)
# Name Status NCT ID Phase Drugs
1 Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Unknown status NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
2 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
3 International Study to Predict Optimised Treatment - in Depression Unknown status NCT00693849 Phase 4 Escitalopram;Sertraline;Venlafaxine-XR
4 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
5 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
6 Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial Unknown status NCT03779789 Phase 4 Vortioxetine;Sertraline;citalopram;Escitalopram;Paroxetine;Fluoxetine;Fluvoxamine
7 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
8 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
9 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
10 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
11 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
12 A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Unknown status NCT02669030 Phase 4 suvorexant;Placebo
13 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
14 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
15 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
16 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
17 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
18 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
19 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
20 A Randomised Pragmatic Trial Comparing the Clinical and Cost Effectiveness of Lithium and Quetiapine Augmentation in Treatment Resistant Depression Unknown status NCT03004521 Phase 4 Quetiapine;Lithium
21 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
22 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
23 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
24 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
25 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
26 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
27 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
28 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
29 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
30 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
31 Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy Unknown status NCT03187093 Phase 4 Vortioxetine;Escitalopram
32 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
33 Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
34 Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial Unknown status NCT03666494 Phase 4 Ketamine Hydrochloride;Propofol;Fentanyl
35 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
36 Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression Unknown status NCT03328052 Phase 4
37 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
38 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
39 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
40 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
41 Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy Unknown status NCT02579642 Phase 4 Ketamine;Placebo
42 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
43 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
44 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
45 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
46 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
47 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
48 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
49 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
50 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Amitriptyline Hydrochloride
Bupropion hydrobromide
Bupropion Hydrochloride
buspirone hydrochloride
Citalopram hydrobromide
Clomipramine Hydrochloride
Desipramine Hydrochloride
Doxepin Hydrochloride
Escitalopram oxalate
Fluoxetine Hydrochloride
Fluvoxamine Maleate
Imipramine Hydrochloride
Imipramine pamoate
Kava preparation
Lithium Aspartate
Lithium Carbonate
lithium citrate
Maprotiline Hydrochloride
Methylphenidate Hydrochloride
Nortriptyline Hydrochloride
Paroxetine Hydrochloride
Phenelzine Sulfate
Pramipexole dihydrochloride
Protriptyline Hydrochloride
selegiline hydrochloride
Sertraline Hydrochloride
Tranylcypromine sulfate
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine Maleate
Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Genetic Tests for Mental Depression

Genetic tests related to Mental Depression:

# Genetic test Affiliating Genes
1 Mental Depression 29

Anatomical Context for Mental Depression

MalaCards organs/tissues related to Mental Depression:

Brain, Cortex, Prefrontal Cortex, Amygdala, Pituitary, Heart, Spinal Cord

Publications for Mental Depression

Articles related to Mental Depression:

(show top 50) (show all 29515)
# Title Authors PMID Year
Attention bias modification in depression: A randomized trial using a novel, reward-based, eye-tracking approach. 61
33202263 2021
Evaluation of mechanism of change in transdiagnostic cognitive behaviour therapy using single case experimental design. 61
33388441 2021
Physiological sensation word usage in social anxiety disorder with and without comorbid depression. 61
33508674 2021
Current application and future directions of photobiomodulation in central nervous diseases. 61
33269767 2021
Lateral hypothalamus orexinergic inputs to lateral habenula modulate maladaptation after social defeat stress. 61
33569507 2021
Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. 61
33346015 2021
Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. 61
33338557 2021
Fronto-limbic neuroimaging biomarkers for diagnosis and prediction of treatment responses in major depressive disorder. 61
33370569 2021
Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+ and TLR4+ Th17/Tc17-like cells in multiple sclerosis patients with major depression. 61
33112414 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorder. 61
33422821 2021
In-Hospital Outcomes in Patients With a History of Malignancy Undergoing Transcatheter Aortic Valve Implantation. 61
33285093 2021
Skin autofluorescence of advanced glycation end products and mortality in affective disorders in the lifelines cohort study: A mediation analysis. 61
33601681 2021
The Maudsley 3-item Visual Analogue Scale (M3VAS): Validation of a scale measuring core symptoms of depression. 61
33418379 2021
Consensus statements on the clinical understanding and use of bupropion in Hong Kong. 61
33555615 2021
Prevalence of DSM-5 mixed features: A meta-analysis and systematic review. 61
33418368 2021
Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. 61
33230268 2021
Transcription Factor TWIST1 Integrates Dendritic Remodeling and Chronic Stress to Promote Depressive-like Behaviors. 61
33190845 2021
A randomized, controlled trial assessing the acute efficacy of triple chronotherapy in unipolar depression. 61
33601689 2021
A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach. 61
33045321 2021
The effects of psychobiotics on the microbiota-gut-brain axis in early-life stress and neuropsychiatric disorders. 61
33069817 2021
Gut microbiota dysbiosis in depressed women: The association of symptom severity and microbiota function. 61
33421868 2021
Disentangling the pathologies linking white matter hyperintensity and geriatric depressive symptoms in subjects with different degrees of vascular impairment. 61
33601672 2021
Validation of the difficulties with emotion regulation scale in a sample of trauma-exposed Black women. 61
32762085 2021
The partial saphenous nerve injury model of pain impairs reward-related learning but not reward sensitivity or motivation. 61
33591111 2021
An alternative approach to future diagnostic standards for major depressive disorder. 61
33049324 2021
The effect of smartphone-based monitoring and treatment on the rate and duration of psychiatric readmission in patients with unipolar depressive disorder: The RADMIS randomized controlled trial. 61
33421863 2021
Parental age and risk of depression: A nationwide, population-based case-control study. 61
33421859 2021
Host genetics influences the relationship between the gut microbiome and psychiatric disorders. 61
33130294 2021
Neuromodulatory effect of curcumin on catecholamine systems and inflammatory cytokines in ovariectomized female rats. 61
33098686 2021
Performance of the Geriatric Depression Scale-15 with Older Adults Aged over 65 Years: An Updated Review 2000-2019. 61
33164674 2021
Reconsidering the reasons for heightened inflammation in major depressive disorder. 61
33422819 2021
Decreased sensitivity to risk levels in ventral stratum in major depressive disorder during risky decision-making. 61
33418366 2021
Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. 61
33445082 2021
Major Depressive Disorder and gut microbiota - Association not causation. A scoping review. 61
32976952 2021
Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. 61
33601706 2021
Editorial for "Decoupling of Gray and White Matter Functional Networks in Medication-Naive Patients With Major Depressive Disorder". 61
33331026 2021
Short-term cerebral blood flow variability in major depressive disorder. 61
33601686 2021
Decoupling of Gray and White Matter Functional Networks in Medication-Naïve Patients With Major Depressive Disorder. 61
33043540 2021
Benefits of animal models to understand the pathophysiology of depressive disorders. 61
32735913 2021
Electroencephalogram patterns in patients comorbid with major depressive disorder and anxiety symptoms: Proposing a hypothesis based on hypercortical arousal and not frontal or parietal alpha asymmetry. 61
33601739 2021
Intrinsic connectivity of the prefrontal cortex and striato-limbic system respectively differentiate major depressive from generalized anxiety disorder. 61
32961541 2021
The risk of anxiety disorders in children of parents with severe psychiatric disorders: a systematic review and meta-analysis. 61
33422825 2021
Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. 61
33601673 2021
Comorbid posttraumatic stress disorder and major depressive disorder are associated with asthma morbidity among World Trade Center workers. 61
33098982 2021
Defining the role of mirtazapine in the treatment of refractory pruritus. 61
31180795 2021
Body mass index and variability in hippocampal volume in youth with major depressive disorder. 61
33422817 2021
Analysis of gut microbiota and intestinal integrity markers of inpatients with major depressive disorder. 61
32827611 2021
New agents and perspectives in the pharmacological treatment of major depressive disorder. 61
33159975 2021
Solid lipid nanoparticles loading with curcumin and dexanabinol to treat major depressive disorder. 61
32985484 2021
Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. 61
32534176 2021

Variations for Mental Depression

Expression for Mental Depression

Search GEO for disease gene expression data for Mental Depression.

Pathways for Mental Depression

GO Terms for Mental Depression

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 SERPINA3 POMC OXT MIRLET7D MIR185 MIR144

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 IL6 HTR2A HTR1A DPP4 CRH
2 female pregnancy GO:0007565 9.63 OXT CRH COMT
3 catecholamine metabolic process GO:0006584 9.49 MAOA COMT
4 neurotransmitter catabolic process GO:0042135 9.43 MAOA COMT
5 sleep GO:0030431 9.4 OXT HTR2A
6 dopamine catabolic process GO:0042420 9.37 MAOA COMT
7 serotonin receptor signaling pathway GO:0007210 9.32 HTR2A HTR1A
8 sperm ejaculation GO:0042713 9.26 SLC6A4 OXT
9 response to ether GO:0045472 9.16 OXT CRH
10 regulation of serotonin secretion GO:0014062 8.96 HTR1A CRH
11 memory GO:0007613 8.92 SLC6A4 OXT HTR2A BDNF

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A

Sources for Mental Depression

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....